Clinical Trials
16
Active:2
Completed:4
Trial Phases
1 Phases
Phase 1:14
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)β’ Click on a phase to view related trials
Phase 1
14 (100.0%)Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 7
- Registration Number
- NCT06425003
- Locations
- πΊπΈ
Fortrea Clinical Research Unit Inc., Madison, Wisconsin, United States
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 72
- Registration Number
- NCT06310876
- Locations
- πΊπΈ
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
Expanded Access to ABBV-CLS-484
- Conditions
- Advanced Solid Tumor Cancer
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Calico Life Sciences LLC
- Registration Number
- NCT06188975
A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06145607
- Locations
- πΊπΈ
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05763459
- Locations
- πΊπΈ
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
- Prev
- 1
- 2
- Next
News
No news found